Picture of Arcus Biosciences logo

RCUS — Arcus Biosciences Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeMid CapNeutral

Momentum

Relative Strength (%)
1m-19.08%
3m-1.94%
6m-1.51%
1yr-24.3%
Volume Change (%)
10d/3m+18.09%
Price vs... (%)
52w High-30.02%
50d MA-16.41%
200d MA+3.66%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-40.07%
Return on Equity-51.22%
Operating Margin-736.81%

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Latest News & Insights for RCUS

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202131st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2021 / 2022

Blurred out image of Arcus Biosciences EPS forecast chart

Profile Summary

Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on cancer therapies. The Company has developed drug discovery capability designed to create differentiated small molecules, which has the ability to develop in combinations with its monoclonal antibodies through rationally designed, indication-specific, adaptive clinical trial designs. It is focused on creating, developing and commercializing differentiated combination cancer therapies. The Company has five products in clinical development: Domvanalimab, Etrumadenant, Quemliclustat, AB308 and Zimberelimab. Domvanalimab is designed for immune activation and tumour clearance in combination with other immunotherapy and anti-cancer agents. Etrumadenant is designed to inhibit the adenosine-driven impairment of tumour-infiltrating lymphocytes and myeloid cells. Quemliclustat is designed to provide differential benefits relative to monoclonal antibodies. AB308 is its Fc-enabled anti-TIGIT monoclonal antibody.

Directors

Last Annual
December 31st, 2020
Last Interim
September 30th, 2021
Incorporated
April 30th, 2015
Public Since
March 15th, 2018
No. of Shareholders
80
No. of Employees
236
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
us flag iconNew York Stock Exchange
Shares in Issue
70,249,475

RCUS Share Price Performance

Latest News for RCUS

Upcoming Events for RCUS

Q4 2021 Arcus Biosciences Inc Earnings Release

Q1 2022 Arcus Biosciences Inc Earnings Release

Arcus Biosciences Inc Annual Shareholders Meeting

Similar to RCUS

Picture of ADC Therapeutics SA logo

ADC Therapeutics SA

us flag iconNew York Stock Exchange

Ambrx Biopharma

us flag iconNew York Stock Exchange

Picture of Annovis Bio logo

Annovis Bio

us flag iconNew York Stock Exchange

FAQ

Or unlock with your email

Or unlock with your email